If a woman is over 35 years old and has been having regular intercourse for 6 months without conceiving, she should be investigated for infertility earlier. Regular sexual intercourse is defined as having intercourse every 2-3 days. However, if a woman is under 35 years old, investigation should wait until after 12 months of regular intercourse. It is important to consider early referral when the female has amenorrhea, previous pelvic surgery, abnormal genital examination, or is suffering from significant systemic illness. Similarly, early referral should be considered for males who have had previous surgery on genitalia, previous STI, varicocele, or abnormal genital examination.

Infertility is a common issue that affects approximately 1 in 7 couples. It is important to note that around 84% of couples who have regular sexual intercourse will conceive within the first year, and 92% within the first two years. The causes of infertility can vary, with male factor accounting for 30%, unexplained causes accounting for 20%, ovulation failure accounting for 20%, tubal damage accounting for 15%, and other causes accounting for the remaining 15%.

When investigating infertility, there are some basic tests that can be done. These include a semen analysis and a serum progesterone test. The serum progesterone test is done 7 days prior to the expected next period, typically on day 21 for a 28-day cycle. The interpretation of the serum progesterone level is as follows: if it is less than 16 nmol/l, it should be repeated and if it remains consistently low, referral to a specialist is necessary. If the level is between 16-30 nmol/l, it should be repeated, and if it is greater than 30 nmol/l, it indicates ovulation.

It is important to counsel patients on lifestyle factors that can impact fertility. This includes taking folic acid, maintaining a healthy BMI between 20-25, and advising regular sexual intercourse every 2 to 3 days. Additionally, patients should be advised to quit smoking and limit alcohol consumption to increase their chances of conceiving.

Memantine is an NMDA receptor antagonist and is not a cholinesterase inhibitor like donepezil and rivastigmine. While memantine does act at the serotonin and dopamine receptors, it acts as an antagonist and agonist respectively, rather than the options given.

Managing Alzheimer’s Disease: Non-Pharmacological and Pharmacological Approaches

Alzheimer’s disease is a type of dementia that progressively affects the brain and is the most common form of dementia in the UK. To manage this condition, there are both non-pharmacological and pharmacological approaches available.

Non-pharmacological management involves offering a range of activities that promote wellbeing and are tailored to the patient’s preferences. Group cognitive stimulation therapy is recommended for patients with mild to moderate dementia, while group reminiscence therapy and cognitive rehabilitation are also options to consider.

Pharmacological management involves the use of medications. The three acetylcholinesterase inhibitors (donepezil, galantamine, and rivastigmine) are options for managing mild to moderate Alzheimer’s disease. Memantine, an NMDA receptor antagonist, is considered a second-line treatment and is recommended for patients with moderate Alzheimer’s who are intolerant of or have a contraindication to acetylcholinesterase inhibitors. It can also be used as an add-on drug to acetylcholinesterase inhibitors for patients with moderate or severe Alzheimer’s or as monotherapy in severe Alzheimer’s.

When managing non-cognitive symptoms, NICE does not recommend antidepressants for mild to moderate depression in patients with dementia. Antipsychotics should only be used for patients at risk of harming themselves or others or when the agitation, hallucinations, or delusions are causing them severe distress.

It is important to note that donepezil is relatively contraindicated in patients with bradycardia, and adverse effects may include insomnia. By utilizing both non-pharmacological and pharmacological approaches, patients with Alzheimer’s disease can receive comprehensive care and management.

Common Elbow Pain Symptoms and Their Features

Elbow pain can be caused by various conditions, each with its own set of symptoms. Here are some common elbow pain symptoms and their features:

1. Lateral Epicondylitis (Tennis Elbow)
– Pain and tenderness localized to the lateral epicondyle
– Pain worsens on resisted wrist extension with the elbow extended or supination of the forearm with the elbow extended
– Episodes typically last between six months and two years; patients tend to have acute pain for 6-12 weeks
– Pain aggravated by wrist flexion and pronation

2. Medial Epicondylitis (Golfer’s Elbow)
– Pain and tenderness localized to the medial epicondyle
– Pain aggravated by wrist flexion and pronation
– Symptoms may be accompanied by numbness/tingling in the fourth and fifth fingers due to ulnar-nerve involvement

3. Cubital Tunnel Syndrome
– Initially intermittent tingling in the fourth and fifth fingers
– Pain worsens when the elbow is resting on a firm surface or flexed for extended periods
– Later numbness in the fourth and fifth fingers with associated weakness

4. Carpal Tunnel Syndrome
– Pain worsens when the wrists are in complete flexion for at least 30 seconds
– The Phalen test is done to investigate its presence

5. Olecranon Bursitis
– Swelling over the posterior aspect of the elbow with associated pain, warmth, and erythema
– Typically affects middle-aged male patients

Understanding Common Symptoms of Elbow Pain

For the acute treatment of migraine, a combination of triptan and NSAID or triptan and paracetamol is recommended. Prophylaxis options include topiramate or propranolol. In this case, the patient’s history is consistent with migraine and prophylaxis with propranolol or topiramate should be considered. Zolmitriptan is not indicated for prophylaxis, but rather for acute treatment of migraine.

Managing Migraines: Guidelines and Treatment Options

Migraines can be debilitating and affect a significant portion of the population. To manage migraines, it is important to understand the different treatment options available. According to the National Institute for Health and Care Excellence (NICE) guidelines, acute treatment for migraines involves a combination of an oral triptan and an NSAID or paracetamol. For young people aged 12-17 years, a nasal triptan may be preferred. If these measures are not effective, non-oral preparations of metoclopramide or prochlorperazine may be considered, along with a non-oral NSAID or triptan.

Prophylaxis should be given if patients are experiencing two or more attacks per month. NICE recommends topiramate or propranolol, depending on the patient’s preference, comorbidities, and risk of adverse events. Propranolol is preferred in women of childbearing age as topiramate may be teratogenic and reduce the effectiveness of hormonal contraceptives. Acupuncture and riboflavin may also be effective in reducing migraine frequency and intensity for some people. For women with predictable menstrual migraines, frovatriptan or zolmitriptan may be recommended as a type of mini-prophylaxis.

Specialists may consider other treatment options, such as candesartan or monoclonal antibodies directed against the calcitonin gene-related peptide (CGRP) receptor, like erenumab. However, pizotifen is no longer recommended due to common adverse effects like weight gain and drowsiness. It is important to exercise caution with young patients as acute dystonic reactions may develop. By following these guidelines and considering various treatment options, migraines can be effectively managed.

Probability of Inheriting Sickle Cell Disease

Sickle cell anaemia is an autosomal recessive condition that affects the haemoglobin in red blood cells. If one parent has sickle cell anaemia (HbSS) and the other is a carrier (HbAS), the baby has a 1 in 2 chance of inheriting the condition. The baby will inherit the HbS allele from the mother and either the HbA or HbS allele from the father, resulting in possible genotypes of HbAS, HbSS, HbAS, or HbSS. This gives the baby a 1 in 2 chance of having sickle cell disease and a 1 in 2 chance of being a carrier.

If both parents are carriers (HbAS), the baby has a 1 in 4 chance of inheriting sickle cell disease. If one parent has the condition and the other is a carrier, there is a 1 in 2 chance the child will inherit the condition. In the case of a heterozygous father and a mother with sickle cell disease, there is a 1 in 3 chance of the baby having the condition. Finally, if both parents are carriers and the baby inherits one HbS allele from each parent, there is a 1 in 8 chance of the baby having sickle cell disease and a 3 in 8 chance of being a carrier. Understanding the probabilities of inheriting sickle cell disease can help individuals make informed decisions about family planning and genetic testing.

Cervical cancer screening now includes testing all samples for hrHPV. If the result is positive, cytology is performed. If the cytology is normal, the test is repeated after 12 months.

Upon repeat testing, if the result is now negative for hrHPV, the patient can resume normal recall. However, if the result is still positive for hrHPV and the cytology is normal, another repeat test should be done after 12 months. This applies to the patient in the given scenario.

If the second repeat test at 24 months is negative for hrHPV, the patient can return to normal recall. However, if the result is positive for hrHPV, they should be referred for colposcopy.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

Dextrose IV is not the recommended treatment for correcting hypoglycemia. If the patient is conscious, a fast-acting glucose liquid should be given. However, if the patient is unconscious or unable to swallow, subcutaneous or intramuscular injection of glucagon may be necessary. While a sandwich can be helpful after treating the hypoglycemic episode, it is not a quick-acting carbohydrate and should not be used in the acute phase.

Understanding Hypoglycaemia: Causes, Symptoms, and Management

Hypoglycaemia is a condition characterized by low blood sugar levels, which can lead to a range of symptoms and complications. There are several possible causes of hypoglycaemia, including insulinoma, self-administration of insulin or sulphonylureas, liver failure, Addison’s disease, and alcohol consumption. The physiological response to hypoglycaemia involves hormonal and sympathoadrenal responses, which can result in a range of symptoms such as sweating, shaking, hunger, weakness, confusion, and even convulsions or coma in severe cases.

It is important to note that blood glucose levels and the severity of symptoms are not always correlated, especially in patients with diabetes. Blood glucose concentrations below 3.3 mmol/L can cause autonomic symptoms, while concentrations below 2.8 mmol/L can cause neuroglycopenic symptoms. Management of hypoglycaemia depends on the severity of the symptoms and the setting in which it occurs. In the community, oral glucose or quick-acting carbohydrates may be given, while in a hospital setting, subcutaneous or intramuscular injection of glucagon or intravenous glucose solution may be necessary.

In summary, hypoglycaemia is a serious condition that requires prompt recognition and management to prevent complications. Understanding the causes, symptoms, and appropriate management strategies can help individuals with diabetes and healthcare professionals to effectively manage this condition.

A baby has been diagnosed with cow’s milk protein intolerance, which is a common condition affecting many infants within the first 3 months of life. The severity of the case is considered mild-moderate, as the baby’s size and weight are appropriate for their age. Primary care can manage this condition initially by switching to an extensive hydrolysed formula. An oral challenge is not recommended, as it is typically reserved for cases with significant diagnostic uncertainty or to determine if a food allergy has resolved. Referral to a paediatrician is not necessary at this stage. If the initial switch to an extensive hydrolysed formula does not alleviate symptoms, an amino acid-based formula can be tried. It is not appropriate to suggest that the mother switch to breastfeeding, as this decision should be respected. Even exclusively breastfed babies can develop cow’s milk protein intolerance, and in those cases, the mother should eliminate cow’s milk from her diet while continuing to breastfeed.

Understanding Cow’s Milk Protein Intolerance/Allergy

Cow’s milk protein intolerance/allergy (CMPI/CMPA) is a condition that affects around 3-6% of children, typically presenting in the first 3 months of life in formula-fed infants. Both immediate and delayed reactions can occur, with CMPA used for immediate reactions and CMPI for mild-moderate delayed reactions. Symptoms include regurgitation, vomiting, diarrhea, urticaria, atopic eczema, colic symptoms, wheeze, chronic cough, and rarely, angioedema and anaphylaxis. Diagnosis is often clinical, with investigations including skin prick/patch testing and total IgE and specific IgE (RAST) for cow’s milk protein.

Management for formula-fed infants includes using extensive hydrolyzed formula (eHF) milk as the first-line replacement formula for mild-moderate symptoms and amino acid-based formula (AAF) for severe CMPA or if no response to eHF. Around 10% of infants are also intolerant to soya milk. For breastfed infants, mothers should eliminate cow’s milk protein from their diet and consider prescribing calcium supplements to prevent deficiency. eHF milk can be used when breastfeeding stops until at least 6 months and up to 12 months of age.

The prognosis for CMPI is usually good, with most children becoming milk tolerant by the age of 3-5 years. However, a challenge is often performed in a hospital setting as anaphylaxis can occur. It is important to refer infants with severe symptoms to a pediatrician for management. Understanding CMPI/CMPA and its management can help parents and healthcare providers provide appropriate care for affected children.

Long-term oxygen therapy is one of the few interventions that has been proven to enhance survival in COPD following smoking cessation.

NICE guidelines recommend smoking cessation advice, annual influenza and one-off pneumococcal vaccinations, and pulmonary rehabilitation for COPD patients. Bronchodilator therapy is first-line treatment, with the addition of LABA and LAMA for patients without asthmatic features and LABA, ICS, and LAMA for those with asthmatic features. Theophylline is recommended after trials of bronchodilators or for patients who cannot use inhaled therapy. Azithromycin prophylaxis is recommended in select patients. Mucolytics should be considered for patients with a chronic productive cough. Loop diuretics and long-term oxygen therapy may be used for cor pulmonale. Smoking cessation and long-term oxygen therapy may improve survival in stable COPD patients. Lung volume reduction surgery may be considered in selected patients.

Treatment Options for COPD Exacerbations: Antibiotics and Corticosteroids

COPD exacerbations are characterized by a sudden worsening of symptoms beyond the patient’s usual stable state. These symptoms include increased breathlessness, cough, sputum production, and changes in sputum color. To treat exacerbations, a combination of antibiotics and corticosteroids is often used.

Oral corticosteroids, such as prednisolone, should be prescribed for five days to patients experiencing a significant increase in breathlessness that interferes with daily activities. Antibiotics are recommended for exacerbations associated with purulent sputum, with first-line agents including amoxicillin, doxycycline, and clarithromycin.

It is important to follow local microbiologist guidance when initiating empirical antibiotic treatment. Flucloxacillin and clindamycin are not useful in treating COPD exacerbations and are recommended for other conditions such as skin infections and bacterial vaginosis, respectively. Nitrofurantoin and trimethoprim are used for urinary tract infections and may be considered as first or second-line agents depending on antibiotic resistance and previous sensitivity.

By the age of 2, children should have the ability to combine two words, indicating normal development. Therefore, there is no need to seek consultation with a paediatric specialist or schedule a follow-up appointment in the near future.

Developmental milestones for speech and hearing are important indicators of a child’s growth and development. These milestones can help parents and caregivers track a child’s progress and identify any potential issues early on. At three months, a baby should be able to quieten to their parents’ voice and turn towards sound. They may also start to squeal. By six months, they should be able to produce double syllables like adah and erleh. At nine months, they may say mama and dada and understand the word no. By 12 months, they should know and respond to their own name and understand simple commands like give it to mummy.

Between 12 and 15 months, a child may know about 2-6 words and understand more complex commands. By two years old, they should be able to combine two words and point to parts of their body. Their vocabulary should be around 200 words by 2 1/2 years old. At three years old, they should be able to talk in short sentences and ask what and who questions. They may also be able to identify colors and count to 10. By four years old, they may start asking why, when, and how questions. These milestones are important to keep in mind as a child grows and develops their speech and hearing abilities.

Bacterial Vaginosis: Symptoms, Risk Factors, and Diagnosis

Bacterial vaginosis (BV) is a common vaginal infection caused by an overgrowth of bacteria. It is important for patients to understand the symptoms, risk factors, and diagnosis of BV in order to properly manage and treat the condition.

Symptoms of BV include vaginal odor, increased vaginal discharge, vulvar irritation, and rarely, dysuria or dyspareunia. Risk factors for BV include recent antibiotic use, decreased estrogen production, presence of an intrauterine device, douching, and sexual activity that could lead to transmission.

Physical findings of BV include grey, thin, and homogeneous vaginal discharge that adheres to the vaginal mucosa, increased light reflex of the vaginal walls, and typically little or no evidence of inflammation. Diagnosis of BV is made through microscopic examination of the discharge, with demonstration of three of the following four Amsel criteria: clue cells on a saline smear, a pH >4.5, characteristic discharge, and a positive whiff test.

Patients with BV should be advised to wash only with hypoallergenic bar soaps or no soap at all, avoid liquid soaps, body washes, and perfumed soaps, and not to douche or use over-the-counter vaginal hygiene products. While studies have shown inconsistent results, some patients may find relief from symptoms by using yogurt containing live bacteria.

It is important to properly manage and treat BV, as long-standing or untreated cases may lead to more serious complications such as endometritis, salpingitis, pelvic inflammatory disease, or pregnancy complications. However, with proper care and attention, the prognosis for uncomplicated cases of BV is generally excellent.

There are several methods for screening and diagnosing Down’s syndrome in pregnancy. The nuchal translucency scan, which measures fluid in the fetal neck, is best done between 11 and 14 weeks and can detect an increased risk of genetic syndromes. The triple screen, which measures levels of certain hormones in the mother’s blood, is done in the second trimester and can detect up to 69% of cases in singleton pregnancies, but may have a higher false positive or false negative in twin pregnancies. Amniocentesis and chorionic villous sampling are invasive diagnostic tests that can detect chromosomal disorders with high accuracy, but carry a small risk of pregnancy loss. The routine anomaly scan should not be used for Down’s syndrome screening. Cell-free fetal DNA screening is a newer method that can detect about 99% of Down’s syndrome pregnancies, but is currently only offered by private clinics at a high cost. A positive screening result suggests an increased risk for Down’s syndrome, and definitive testing with chorionic villous sampling or amniocentesis is indicated.

If an individual has a family history of breast cancer and ovarian cancer, they should be referred to a breast clinic at a younger age. This is especially important if they have a first-degree or second-degree relative who was diagnosed with breast cancer at any age, as well as a first-degree or second-degree relative who was diagnosed with ovarian cancer at any age (with one of these relatives being a first-degree relative). It is not safe to wait for routine screening, as there may be a risk of familial breast cancer. It is also important to note that breast cancer can still be present even if there is no lump detected during examination. A colonoscopy is not necessary in this case, as the individual is at an increased risk of breast cancer.

Breast cancer screening is offered to women aged 50-70 years through the NHS Breast Screening Programme. Mammograms are provided every three years, and women over 70 years are encouraged to make their own appointments. While the effectiveness of breast screening is debated, it is estimated that the programme saves around 1,400 lives annually.

For those with familial breast cancer, NICE guidelines recommend referral if there is a family history of breast cancer with any of the following: diagnosis before age 40, bilateral breast cancer, male breast cancer, ovarian cancer, Jewish ancestry, sarcoma in a relative under 45 years, glioma or childhood adrenal cortical carcinomas, complicated patterns of multiple cancers at a young age, or paternal history of breast cancer with two or more relatives on the father’s side. Women at increased risk due to family history may be offered screening at a younger age. Referral to a breast clinic is recommended for those with a first-degree relative diagnosed with breast cancer before age 40, a first-degree male relative with breast cancer, a first-degree relative with bilateral breast cancer before age 50, two first-degree relatives or one first-degree and one second-degree relative with breast cancer, or a first- or second-degree relative with breast and ovarian cancer.

Understanding Topical Treatments for Skin Conditions

Athlete’s foot is a common fungal infection that affects the toe webs and is often caused by excess moisture. The first-line treatment for this condition is a topical antifungal such as miconazole or terbinafine cream, which should be used twice daily for four weeks. If there is no improvement, further investigations may be required, and oral antifungals may be prescribed. It is important to advise patients on foot hygiene and to avoid walking barefoot in communal areas.

Dithranol is a topical treatment for psoriasis, a condition that presents as large, scaly plaques with a symmetrical distribution. This is different from athlete’s foot, which is characterized by a moist, peeling rash between the toes. Emollients, which are topical moisturizers, are used for atopic eczema management and have no role in treating athlete’s foot.

Oral terbinafine is reserved for severe or extensive fungal infections that cannot be treated with topical antifungal agents. Finally, while an antifungal/topical steroid combination may reduce symptoms more rapidly in cases of inflamed tissue, it has no overall benefit. Moderately potent topical steroids such as eumovate are more appropriate for managing atopic eczema.

The management of tuberculosis has been outlined in guidelines by the British Thoracic Society. It is recommended that liver function tests are conducted in all cases and monitored during treatment. Prior to starting ethambutol, it is important to check visual acuity and renal function.

Side-Effects and Mechanism of Action of Tuberculosis Drugs

Rifampicin is a drug that inhibits bacterial DNA dependent RNA polymerase, which prevents the transcription of DNA into mRNA. However, it is a potent liver enzyme inducer and can cause hepatitis, orange secretions, and flu-like symptoms.

Isoniazid, on the other hand, inhibits mycolic acid synthesis. It can cause peripheral neuropathy, which can be prevented with pyridoxine (Vitamin B6). It can also cause hepatitis and agranulocytosis. Additionally, it is a liver enzyme inhibitor.

Pyrazinamide is converted by pyrazinamidase into pyrazinoic acid, which in turn inhibits fatty acid synthase (FAS) I. However, it can cause hyperuricaemia, leading to gout, as well as arthralgia, myalgia, and hepatitis.

Lastly, Ethambutol inhibits the enzyme arabinosyl transferase, which polymerizes arabinose into arabinan. It can cause optic neuritis, so it is important to check visual acuity before and during treatment. Additionally, the dose needs adjusting in patients with renal impairment.

In summary, these tuberculosis drugs have different mechanisms of action and can cause various side-effects. It is important to monitor patients closely and adjust treatment accordingly to ensure the best possible outcomes.

Understanding Multiple Myeloma: A Malignant Disease of Plasma Cells

Multiple myeloma is a malignant disease of plasma cells that commonly affects adults aged over 60 years. It is characterized by the production of paraproteinaemia in the blood, which can affect multiple organs including the blood, bone, kidneys, and immune system. The most common symptoms of multiple myeloma include unexplained bone pain, hypercalcaemia, weight loss, hyperviscosity symptoms, spinal cord compression, and fever.

On the other hand, osteoporosis is a condition characterized by low bone mass and deterioration of the structure of the bone tissue, resulting in bone fragility and susceptibility to fracture. Multiple vertebral collapses and lytic lesions are more sinister in nature and are commonly associated with multiple myeloma.

Osteosarcoma, bone metastases, and chronic myeloblastic leukaemia (CML) are not related to multiple myeloma. Osteosarcoma is characterized by cortical destruction and the presence of a soft-tissue mass, while bone metastases usually lead to destruction of the cortex on plain radiographs. Symptoms of CML include fatigue, night sweats, weight loss, abdominal fullness, and left upper quadrant pain.

In summary, understanding the symptoms and characteristics of multiple myeloma is crucial in diagnosing and treating this malignant disease of plasma cells.

NICE recommends using the CHA2DS2-VASc score to determine the need for anticoagulation in patients with any history of AF.

The ORBIT scoring system should be used to assess bleeding risk, but anticoagulation should not be withheld solely on the grounds of age or risk of falls.

DOACs are now recommended as the first-line anticoagulant for patients with AF, with warfarin used second-line if a DOAC is contraindicated or not tolerated. Aspirin is not recommended for reducing stroke risk in patients with AF.

When an abdominal wound reopens after surgery, it is called wound dehiscence. This can happen for various reasons, including infection, poor surgical technique, and malnutrition. As a junior doctor, it is important to know how to manage this emergency situation. The initial steps involve administering broad-spectrum antibiotics intravenously, covering the wound with sterile gauze soaked in sterile saline to prevent the abdominal contents from drying out, and arranging for the patient to undergo wound repair in the operating theatre. It is not advisable to attempt to close the wound on the ward, as this can be unsafe and increase the risk of infection or bowel injury. A nasogastric tube is not necessary, and simply redressing the wound without moist gauze can lead to fluid loss from the abdominal contents. It is also not necessary to arrange a CT scan, as the problem is evident and requires immediate management. While antibiotics and surgery are necessary, leaving the wound open and uncovered can lead to fluid loss and infection.

Abdominal wound dehiscence is a serious issue that surgeons who perform abdominal surgery frequently encounter. It occurs when all layers of an abdominal mass closure fail, resulting in the protrusion of the viscera externally. This condition is associated with a 30% mortality rate and can be classified as either superficial or complete, depending on the extent of the wound failure.

Several factors increase the risk of abdominal wound dehiscence, including malnutrition, vitamin deficiencies, jaundice, steroid use, major wound contamination (such as faecal peritonitis), and poor surgical technique. To prevent this condition, the preferred method is the mass closure technique, also known as the Jenkins Rule.

When sudden full dehiscence occurs, the wound should be covered with saline impregnated gauze, and the patient should receive IV broad-spectrum antibiotics, analgesia, and IV fluids. Arrangements should also be made for a return to the operating theatre.

The appropriate way to address the patient is as a 2-week wait referral. According to the NICE Guidelines for suspected cancer referrals, if a hard, irregular prostate indicative of prostate carcinoma is detected during rectal examination, urgent referral is necessary. Along with the referral, the PSA test result should also be included. It is important to note that the PSA test is not always reliable in detecting prostate cancer, as around 1 in 50 men with fast-growing prostate cancer have a normal PSA level.

Prostate specific antigen (PSA) is an enzyme produced by both normal and cancerous prostate cells. It is commonly used as a marker for prostate cancer, but its effectiveness as a screening tool is still debated. The NHS Prostate Cancer Risk Management Programme (PCRMP) has released guidelines for handling requests for PSA testing in asymptomatic men. While a recent European trial showed a reduction in prostate cancer deaths, it also revealed a high risk of over-diagnosis and over-treatment. As a result, the National Screening Committee has decided not to introduce a screening programme, but rather allow men to make an informed decision. The PCRMP recommends age-adjusted upper limits for PSA levels, while NICE Clinical Knowledge Summaries suggest a lower threshold for referral. PSA levels can also be raised by factors such as benign prostatic hyperplasia, prostatitis, and urinary tract infections.

The specificity and sensitivity of PSA testing are poor, with a significant number of men with elevated PSA levels not having prostate cancer, and some with normal PSA levels having the disease. Various methods are used to add meaning to PSA levels, including age-adjusted upper limits and monitoring changes in PSA levels over time. It is also debated whether digital rectal examination causes a rise in PSA levels. It is important to note that PSA testing should be postponed after certain events, such as ejaculation or instrumentation of the urinary tract.